圣达生物(603079) - 2020 Q1 - 季度财报

Financial Performance - Operating revenue rose by 62.17% to CNY 196,538,500.10 compared to the same period last year[6] - Net profit attributable to shareholders surged by 342.36% to CNY 62,427,534.02 year-on-year[6] - Basic earnings per share increased by 307.69% to CNY 0.53[6] - The company reported a net profit before tax of ¥12,198,793.13, a significant increase of 364.37% from ¥2,626,927.78 in the previous year, driven by higher total profit[13] - Operating profit for Q1 2020 was ¥73,636,310.57, up 328.5% from ¥17,178,252.37 in the same period last year[26] - Net profit attributable to shareholders for Q1 2020 was ¥62,427,534.02, a substantial rise of 342.5% compared to ¥14,112,251.27 in Q1 2019[27] - The company’s total profit for Q1 2020 was CNY 73,273,665.88, compared to CNY 8,529,909.26 in Q1 2019[29] Assets and Liabilities - Total assets increased by 4.07% to CNY 1,594,920,359.59 compared to the end of the previous year[6] - Current assets totaled CNY 782,001,824.16, up from CNY 720,452,870.27, indicating an increase of about 8.5%[18] - Total liabilities decreased to CNY 384,591,628.53 from CNY 620,880,738.09, a reduction of about 38%[20] - Total equity increased to CNY 1,210,328,731.06 from CNY 911,708,901.40, representing a growth of around 32.8%[20] - Total liabilities decreased to ¥243,267,002.50 in Q1 2020 from ¥446,964,578.63 in Q1 2019, indicating a reduction of 45.5%[26] Cash Flow - Cash flow from operating activities showed a net outflow of CNY 3,308,022.72, compared to a net inflow of CNY -342,344.60 in the previous year[6] - Cash inflow from investment activities was CNY 40,000,000.00 in Q1 2020, a substantial increase from CNY 15,651,787.67 in Q1 2019[32] - Cash flow from financing activities generated a net inflow of CNY 45,104,274.99 in Q1 2020, compared to CNY 58,510,606.10 in Q1 2019[33] - The company reported a decrease in cash received from sales of goods and services, totaling CNY 128,081,426.61 in Q1 2020, compared to CNY 119,562,947.56 in Q1 2019[32] Investments and Expenses - The company made an investment of ¥10,200,000.00 in Tian Tai Yin Kang Bio-pharmaceutical Co., Ltd., reflecting a 70.00% increase in investment payments compared to the previous year[13] - The company’s management expenses rose by 54.78% to ¥21,569,275.55, primarily due to increased employee compensation and fixed asset depreciation[12] - Tax expenses increased by 270.83% to ¥14,757,455.49, mainly due to an increase in corporate income tax and value-added tax payable at the end of the period[12] - Research and development expenses for Q1 2020 were ¥4,631,489.97, slightly up from ¥4,512,795.41 in Q1 2019[26] Other Financial Metrics - The weighted average return on equity increased by 4.04 percentage points to 5.81%[6] - Accounts receivable increased by 67.42% to CNY 174,620,131.12 due to increased sales revenue[11] - The company received government subsidies amounting to CNY 3,456,894.17 during the reporting period[9] - The company reported a financial expense of -¥915,060.44 in Q1 2020, a significant improvement compared to ¥3,935,073.83 in Q1 2019[26]